Cargando…

Gaucher Disease: Transcriptome Analyses Using Microarray or mRNA Sequencing in a Gba1 Mutant Mouse Model Treated with Velaglucerase alfa or Imiglucerase

Gaucher disease type 1, an inherited lysosomal storage disorder, is caused by mutations in GBA1 leading to defective glucocerebrosidase (GCase) function and consequent excess accumulation of glucosylceramide/glucosylsphingosine in visceral organs. Enzyme replacement therapy (ERT) with the biosimilar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dasgupta, Nupur, Xu, You-Hai, Oh, Sunghee, Sun, Ying, Jia, Li, Keddache, Mehdi, Grabowski, Gregory A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790783/ https://www.ncbi.nlm.nih.gov/pubmed/24124461 http://dx.doi.org/10.1371/journal.pone.0074912

Ejemplares similares

Comparative Therapeutic Effects of Velaglucerase Alfa and Imiglucerase in a Gaucher Disease Mouse Model
por: Xu, You-Hai, et al.
Publicado: (2010)

Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial
por: Pleat, Rebecca, et al.
Publicado: (2016)

Seven‐year safety and efficacy with velaglucerase alfa for treatment‐naïve adult patients with type 1 Gaucher disease
por: Zimran, Ari, et al.
Publicado: (2015)

Substrate Compositional Variation with Tissue/Region and Gba1 Mutations in Mouse Models–Implications for Gaucher Disease
por: Sun, Ying, et al.
Publicado: (2013)

A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability
por: Pastores, Gregory M., et al.
Publicado: (2014)

Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials
por: Hughes, Derralynn A, et al.
Publicado: (2015)

Long-term safety and effectiveness of velaglucerase alfa in Gaucher disease: 6-year interim analysis of a post-marketing surveillance in Japan
por: Sagara, Rieko, et al.
Publicado: (2021)

Review of the safety and efficacy of imiglucerase treatment of Gaucher disease
por: Elstein, Deborah, et al.
Publicado: (2009)

Imiglucerase in the treatment of Gaucher disease: a history and perspective
por: Deegan, Patrick B, et al.
Publicado: (2012)

Enzyme replacement therapy with taliglucerase alfa: 36‐month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase
por: Pastores, Gregory M., et al.
Publicado: (2016)

Reversal of life-threatening hepatopulmonary syndrome in Gaucher disease by imiglucerase enzyme replacement therapy
por: Beshlawy, Amal El, et al.
Publicado: (2019)

Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review
por: Doneda, Divair, et al.
Publicado: (2013)

Achievement of Therapeutic Goals with Low-Dose Imiglucerase in Gaucher Disease: A Single-Center Experience
por: Tukan, Irina, et al.
Publicado: (2013)

Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy
por: Serratrice, Christine, et al.
Publicado: (2016)

Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial
por: Schiffmann, Raphael, et al.
Publicado: (2022)

GBA1 variants in Brazilian Gaucher disease patients
por: Basgalupp, Suelen Porto, et al.
Publicado: (2023)

Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment
por: Weinreb, Neal J., et al.
Publicado: (2012)

Impact of Imiglucerase Supply Shortage on Clinical and Laboratory Parameters in Norrbottnian Patients with Gaucher Disease Type 3
por: Machaczka, Maciej, et al.
Publicado: (2014)

The Clinical Efficacy of Imiglucerase versus Eliglustat in Patients with Gaucher's Disease Type 1: A Systematic Review
por: Nabizadeh, Azita, et al.
Publicado: (2018)

Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2017)

Clinical response to eliglustat in treatment-naïve patients with Gaucher disease type 1: Post-hoc comparison to imiglucerase-treated patients enrolled in the International Collaborative Gaucher Group Gaucher Registry
por: Ibrahim, Jennifer, et al.
Publicado: (2016)

Erratum to: Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment
por: Weinreb, Neal J., et al.
Publicado: (2013)

Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1
por: Stirnemann, Jérôme, et al.
Publicado: (2015)

Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series
por: Serratrice, Christine, et al.
Publicado: (2015)

Analysis of glucocerebrosidase (GBA) gene mutations in Iranian patients with Gaucher disease
por: MOZAFARI, Hadi, et al.
Publicado: (2021)

The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients
por: Deegan, Patrick, et al.
Publicado: (2021)

Impact on bone microarchitecture and failure load in a patient with type I Gaucher disease who switched from Imiglucerase to Eliglustat
por: Sidhu, Karamjot, et al.
Publicado: (2020)

Gaucher disease: clinical phenotypes and refining GBA mutational spectrum in Thai patients
por: Phetthong, Tim, et al.
Publicado: (2021)

Identification of novel mutations in glucocerebrosidase (GBA) gene in Indian patients with gaucher disease (GD)
por: Ankleshwaria, Chitra, et al.
Publicado: (2014)

GBA, Gaucher Disease, and Parkinson’s Disease: From Genetic to Clinic to New Therapeutic Approaches
por: Riboldi, Giulietta M., et al.
Publicado: (2019)

Small Molecule Chaperones for the Treatment of Gaucher Disease and GBA1-Associated Parkinson Disease
por: Han, Tae-Un, et al.
Publicado: (2020)

The molecular mechanism of Gaucher disease caused by compound heterozygous mutations in GBA1 gene
por: Liu, Qi, et al.
Publicado: (2023)

Breastfeeding in patients with Gaucher disease: Is taliglucerase alfa safe?
por: Paskulin, Livia, et al.
Publicado: (2019)

Drosophila melanogaster Mutated in its GBA1b Ortholog Recapitulates Neuronopathic Gaucher Disease
por: Cabasso, Or, et al.
Publicado: (2019)

A novel mutation deep within intron 7 of the GBA gene causes Gaucher disease
por: Malekkou, Anna, et al.
Publicado: (2020)

Rare GBA1 genotype associated with severe bone disease in Gaucher disease type 1
por: d'Avila Paskulin, Livia, et al.
Publicado: (2019)

Impact of Gba2 on neuronopathic Gaucher’s disease and α-synuclein accumulation in medaka (Oryzias latipes)
por: Nakanishi, Etsuro, et al.
Publicado: (2021)

Comprehensive short and long read sequencing analysis for the Gaucher and Parkinson’s disease-associated GBA gene
por: Toffoli, Marco, et al.
Publicado: (2022)

Expression of Human Gaucher Disease Gene GBA Generates Neurodevelopmental Defects and ER Stress in Drosophila Eye
por: Suzuki, Takahiro, et al.
Publicado: (2013)

Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study
por: Sims, KB, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_d77aoamv85r7lg4g0msgnohk5j